About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

BARCELONA -- A rheumatology trainee who went on TikTok to find information on her own condition may have uncovered a novel ...

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...

New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.